![Bruce Robinson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bruce Robinson
Président chez
MAYNE PHARMA GROUP LIMITED
Fortune : 132 719 $ au 31/05/2026
Profil
Bruce G.
Robinson is Non-Executive Chairman at Mayne Pharma Group Ltd. starting 2026, Chairman-Research at Northern Sydney Local Health District, Independent Non-Executive Director at Cochlear Ltd. since 2016, Independent Non-Executive Director at Healius Ltd. starting 2026, Non-Executive Director at CS Pharmaceuticals Ltd. starting 2024, Director at Anzac Research Institute, Director at Qbiotics Pty Ltd. since 2015, Independent Non-Executive Director at Ecofibre Ltd. since 2021, and Professor at The University of New South Wales.
Former roles include Chairman at Royal Australian College of General Practitioners, Hoc Mai Medical Foundation, and National Health & Medical Research Council; Director at The Royal Flying Doctor Service of Australia, Centenary Institute, Firefly International Ltd., Digital Health Crc Pty Ltd., Woolcock Institute of Medical Research; Non-Executive Director at Qbiotics Group Ltd. and Lorica Health Pty Ltd.; Head-Medicine at Royal North Shore Hospital; Head-Cancer Genetics Unit at Kolling Institute for Medical Research; Dean at Sydney Medical School; and Advisor at HealthCo Healthcare & Wellness REIT.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/02/2026 | 1 438 ( 0 % ) | 103 981 $ | 31/05/2026 | |
MAYNE PHARMA GROUP LTD. 0,02 % | 30/06/2025 | 16 642 ( 0,02 % ) | 28 737 $ | 31/05/2026 |
Postes actifs de Bruce Robinson
| Sociétés | Poste | Début |
|---|---|---|
| MAYNE PHARMA GROUP LIMITED | Président | 14/01/2026 |
| COCHLEAR LIMITED | Directeur/Membre du Conseil | 13/12/2016 |
| ECOE LITD | Directeur/Membre du Conseil | 04/03/2021 |
| HEALIUS LIMITED | Directeur/Membre du Conseil | 02/02/2026 |
CS Pharmaceuticals Ltd. | Directeur/Membre du Conseil | 24/10/2024 |
Northern Sydney Local Health District | Corporate Officer/Principal | - |
Qbiotics Pty Ltd.
 Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers. | Directeur/Membre du Conseil | 01/01/2015 |
Anzac Research Institute | Directeur/Membre du Conseil | - |
The University of New South Wales
 The University of New South Wales Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Bruce Robinson
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░ ░░░░░ ░░░░░░ ░░░░░░ ░░░░░░░ ░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
67
Relations au 1er degré
23
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 23 |
|---|---|
Cochlear Ltd.
 Cochlear Ltd. Medical SpecialtiesHealth Technology Develops, manufactures and markets implantable hearing solutions | Health Technology |
Healius Ltd.
 Healius Ltd. Medical/Nursing ServicesHealth Services Provides healthcare technology solutions | Health Services |
The University of New South Wales
The University of New South Wales Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Health & Medical Research Council
 National Health & Medical Research Council General GovernmentGovernment Supports health and medical research; for developing health advice for the Australian community, health professionals and governments; and for providing advice on ethical behaviour in health care and in the conduct of health and medical research. | Government |
The Royal Flying Doctor Service of Australia
 The Royal Flying Doctor Service of Australia Medical/Nursing ServicesHealth Services Operates as a aeromedical organisation which offers primary health care and 24-hour emergency services | Health Services |
Centenary Institute
 Centenary Institute Miscellaneous Commercial ServicesCommercial Services Provides medical research services focusing on the diagnosis, prevention, and treatment of diseases | Commercial Services |
Royal Australian College of General Practitioners
 Royal Australian College of General Practitioners Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mayne Pharma Group Ltd.
 Mayne Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company, which develops and manufactures proprietary and generic products | Health Technology |
Royal North Shore Hospital
 Royal North Shore Hospital Hospital/Nursing ManagementHealth Services Operates as a hospital | Health Services |
Woolcock Institute of Medical Research | |
Kolling Institute for Medical Research
 Kolling Institute for Medical Research Miscellaneous Commercial ServicesCommercial Services Operates as a medical research institute | Commercial Services |
Sydney Medical School
 Sydney Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Firefly International Ltd.
 Firefly International Ltd. Wholesale DistributorsDistribution Services Supplies drilling, boring and other equipments | Distribution Services |
Hoc Mai Medical Foundation | |
Anzac Research Institute | |
Qbiotics Pty Ltd.
Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers. | |
Northern Sydney Local Health District | |
Ecofibre Ltd.
 Ecofibre Ltd. TextilesProcess Industries Manufactures and distributes textiles and products made from hemp | Process Industries |
Lorica Health Pty Ltd.
 Lorica Health Pty Ltd. Data Processing ServicesTechnology Services Provides analytics for healthcare data protection, claims and fraud detection services | Technology Services |
Digital Health Crc Pty Ltd. | |
Qbiotics Group Ltd.
 Qbiotics Group Ltd. BiotechnologyHealth Technology Develops novel cell-signaling small molecules derived from natural sources for medical use | Health Technology |
HealthCo Healthcare & Wellness REIT
 HealthCo Healthcare & Wellness REIT Real Estate Investment TrustsFinance Operates as a real estate investment trust which invests in hospitals, aged care, childcare, life sciences & research and primary care & wellness properties | Finance |
CS Pharmaceuticals Ltd. |
